Results 211 to 220 of about 14,917 (240)

Hypomethylating agents in acute lymphoblastic leukemia: untapped potential?

Leukemia & Lymphoma, 2010
Based on pre-clinical data showing patterns of aberrant methylation in myelodysplastic syndromes (MDS) and evidence of cellular differentiation associated with reversal of methylation by decitabine [1–3], MDS became a prime candidate for development of the hypomethylating agents decitabine and 5-azacytidine.
Virginia M, Klimek, Martin S, Tallman
openaire   +2 more sources

Use of hypomethylating agents in myelodysplastic syndromes.

Clinical advances in hematology & oncology : H&O, 2007
Aberrant DNA methylation is one of the molecular hallmarks of cancer and leukemia. By repressing gene expression, it is considered a functional equivalent to the physical inactivation of tumor suppressor genes by deletions or mutations. To clinically exploit this process, compounds with DNA hypomethylating properties have been evaluated both in the ...
Ehab, Atallah, Guillermo, Garcia-Manero
openaire   +1 more source

Acute Myocarditis Induced by Hypomethylating Agents

Journal of Clinical Oncology, 2011
Jean-Emmanuel, Bibault, Nathalie, Cambier, Jean-Michel, Lemahieu, Bruno, Quesnel, Marine, Auffret, Christian, Rose   +5 more
openaire   +2 more sources

Treatment of Hematologic Malignancies with DNA Hypomethylating Agents

2013
The azanucleosides 5-azacytidine (5-aza, Vidaza) and its deoxyribonucleoside analog 5-aza-2′ deoxycytidine (decitabine), while first synthesized and shown to have/possess [besitzen] antileukemic activity in 1964, have only recently been approved for the treatment of myeloid neoplasias.
Michael Daskalakis, Tina E. Joeckel, Michael Lübbert, A. Kuendgen   +3 more
openaire   +1 more source

Molecular imaging in oncology: Current impact and future directions

Ca-A Cancer Journal for Clinicians, 2022
Steven P Rowe, Martin G Pomper
exaly  

Treatment of muscle‐invasive and advanced bladder cancer in 2020

Ca-A Cancer Journal for Clinicians, 2020
Vaibhav G Patel, William K Oh, Matthew D Galsky   +2 more
exaly  

Systemic therapy for hormone receptor‐positive/human epidermal growth factor receptor 2‐negative early stage and metastatic breast cancer

Ca-A Cancer Journal for Clinicians, 2023
Laura A Huppert, Hope S Rugo
exaly  

Chimeric antigen receptor T‐cell therapy in multiple myeloma: A comprehensive review of current data and implications for clinical practice

Ca-A Cancer Journal for Clinicians, 2023

exaly  

Recent progress in the treatment of cancer in children

Ca-A Cancer Journal for Clinicians, 2021
Theodore W Laetsch
exaly  

Hypomethylating Agents

2008
openaire   +1 more source